VolitionRx (NYSE: VNRX) details Q2 2025 results, call set

Rhea-AI Filing Summary

VolitionRx Limited filed a current report describing that it has released its financial results and business updates for the quarter ended June 30, 2025. The company issued a press release on August 14, 2025 and scheduled a conference call for August 15, 2025 at 8:30 a.m. U.S. Eastern Time to discuss these results. The press release containing the detailed financial information and updates is included as Exhibit 99.1 to the report and is being furnished rather than filed under the securities laws.

0000093314false00000933142025-08-142025-08-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 14, 2025

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware		001-36833		91-1949078
(State or other jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

1489 West Warm Springs Road, Suite 110

Henderson, Nevada 89014

(Address of principal executive offices and Zip Code)

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock,par value $0.001 per share		VNRX		NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 ofthe Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

VOLITIONRX LIMITED

Form 8-K

Current Report

Item 2.02. Results of Operations and Financial Condition.

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

On August 14, 2025, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended June 30, 2025. The Company also confirmed its conference call to be held on August 15, 2025 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release of VolitionRx Limited, dated August 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VOLITIONRX LIMITED
Date August 14, 2025	By:	/s/ Cameron Reynolds
		Cameron Reynolds
		Chief Executive Officer & President

3

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release of VolitionRx Limited, dated August 14, 2025.

4

FAQ

What did VolitionRx Limited (VNRX) file in this 8-K?

VolitionRx Limited filed a current report to indicate that it has released financial results and certain business updates for the quarter ended June 30, 2025, and to furnish the related press release as an exhibit.

Which period’s results are covered in VolitionRx (VNRX) latest update?

The update covers VolitionRx Limited’s financial results and business developments for the quarter ended June 30, 2025.

What is included in Exhibit 99.1 for VolitionRx (VNRX)?

Exhibit 99.1 contains the press release of VolitionRx Limited dated August 14, 2025, which presents the company’s quarterly financial results and certain business updates.

When is VolitionRx (VNRX) holding its conference call on these results?

VolitionRx Limited confirmed a conference call to discuss the quarter’s results and updates on August 15, 2025 at 8:30 a.m. U.S. Eastern Time.

Is the VolitionRx (VNRX) press release considered filed or furnished?

The press release included as Exhibit 99.1 is being furnished in accordance with General Instruction B.2. and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Does this 8-K itself provide detailed financial numbers for VolitionRx (VNRX)?

The current report refers readers to the press release in Exhibit 99.1 for detailed financial results and business updates rather than listing those figures in the body of the report.